Abstract:Background: Malignant transformation is associated with tumor aggressiveness and poor patient outcome. This cellular alteration is due to either activation of oncogenes or the silencing of tumor suppressor genes. NKX2-1 was identified as a lineage-specific gene downregulated in poorly differentiated lung adenocarcinoma (LUAD). However, the molecular mechanism and functional role of infiltrated immune cells in NKX2-1-negative tumors are not clearly understood. Methods: Clinical relevance of NKX2-1 expression and disease status were evaluated by immunohistochemical analysis of LUAD tissue arrays and the overall survival analysis of TCGA databases. In vitro and in vivo experiments were applied to confirm the role and mechanisms of NKX2-1 actions in transformed cells. The secretion of chemokines was evaluated by using chemokine array. Flow cytometry and single-cell RNA sequencing analysis of mouse tumor tissue were used to demonstrate the infiltration of neutrophils in mouse models. Results: Low expression of NKX2-1 was observed in high-grade LUAD tumors. LUAD patients who express a pattern of NKX2-1high/TGF-βlow had better survival outcomes than those with NKX2-1low/TGF-βhigh. Mechanistically, TGF-β induced the downregulation of NKX2-1 which led to enhanced epithelial-mesenchymal transition (EMT), cell motility, and CXC chemokine expression. The high release of these chemoattractants promoted the recruitment of neutrophils. Meanwhile, NKX2-1-dependent suppression of CXC chemokines gene expression may be via repressive histone methylation at the promoter region of CXC chemokines in lung cancer cells. In the in vivo syngeneic LUAD models, exacerbated neutrophil infiltration was noted. Single-cell RNA sequencing and flow cytometry both revealed that neutrophils were recruited via CXCLs/CXCR2 activation in LUAD tumors with NKX2-1 knockdown. Conclusion: Our data showed that NKX2-1 represses tumor growth, metastasis, and neutrophil recruitment via the CXCLs/CXCR2-dependent mechanisms. Notably, targeting CXCR2 in NKX2-1-negative tumors may improve LUAD patient outcomes. Citation Format: Shih-Hwa Chiou, Ping-Hsing Tsai, Mong-Lien Wang. Repression of NKX2-1 promote epithelial-mesenchymal transition and tumor neutrophil recruitment in lung cancer progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 212.

An NKX2-1/ERK/WNT feedback loop modulates gastric identity and response to targeted therapy in lung adenocarcinoma

Nkx2-1: a Novel Tumor Biomarker of Lung Cancer

Opposing lineage specifiers induce a pro-tumor hybrid-identity state in lung adenocarcinoma

Abstract 1242: Foxa1/2-dependent epigenomic reprogramming drives lineage switching in lung adenocarcinoma

Long Non-Coding RNA BC087858 Induces Non-T790m Mutation Acquired Resistance to EGFR-TKIs by Activating PI3K/AKT and MEK/ERK Pathways and EMT in Non-Small-cell Lung Cancer

Interplay Of Mkp-1 And Nrf2 Drives Tumor Growth And Drug Resistance In Non-Small Cell Lung Cancer

Abstract 6600: Investigating molecular regulators of a dual identity state in lung adenocarcinoma

Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer

Inactivation of ABL kinases suppresses non-small cell lung cancer metastasis.

Microarray Expression Profile of Long Non-Coding Rnas in Egfr-Tkis Resistance of Human Non-Small Cell Lung Cancer

Neutrophils Recruited by NKX2-1 Suppression via Activation of CXCLs/CXCR2 Axis Promote Lung Adenocarcinoma Progression

Neurokinin-1 Receptor Promotes Non-Small Cell Lung Cancer Progression Through Transactivation of EGFR.

Abstract 212: Repression of NKX2-1 promote epithelial-mesenchymal transition and tumor neutrophil recruitment in lung cancer progression

Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer

EHMT2-mediated transcriptional reprogramming drives neuroendocrine transformation in non-small cell lung cancer

Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition

Effect Of Fgfri On Epithelial-Mesenchymal Transition And Egfr Resistance In Hnc: A Systems Biology Approach

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2

Epidermal growth factor receptor regulates lineage plasticity driving transformation to small cell lung cancer

Kras(G12D) and Nkx2-1 Haploinsufficiency Induce Mucinous Adenocarcinoma of the Lung.